Lineage Cell Therapeutics Past Earnings Performance
Past criteria checks 0/6
Lineage Cell Therapeutics's earnings have been declining at an average annual rate of -4.5%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been growing at an average rate of 29% per year.
Key information
-4.5%
Earnings growth rate
-1.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 29.0% |
| Return on equity | -36.2% |
| Net Margin | -391.0% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How Lineage Cell Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 6 | -24 | 14 | 16 |
| 31 Mar 24 | 8 | -24 | 14 | 16 |
| 31 Dec 23 | 9 | -21 | 14 | 16 |
| 30 Sep 23 | 9 | -23 | 17 | 8 |
| 30 Jun 23 | 11 | -22 | 18 | 8 |
| 31 Mar 23 | 12 | -24 | 19 | 11 |
| 31 Dec 22 | 15 | -26 | 23 | 14 |
| 30 Sep 22 | 14 | -49 | 23 | 35 |
| 30 Jun 22 | 13 | -51 | 23 | 34 |
| 31 Mar 22 | 9 | -49 | 23 | 34 |
| 31 Dec 21 | 4 | -43 | 18 | 34 |
| 30 Sep 21 | 4 | -12 | 17 | 12 |
| 30 Jun 21 | 2 | -12 | 16 | 12 |
| 31 Mar 21 | 2 | -14 | 15 | 12 |
| 31 Dec 20 | 2 | -21 | 16 | 12 |
| 30 Sep 20 | 3 | -27 | 16 | 13 |
| 30 Jun 20 | 3 | -36 | 17 | 14 |
| 31 Mar 20 | 3 | -59 | 18 | 16 |
| 31 Dec 19 | 4 | -12 | 19 | 18 |
| 30 Sep 19 | 3 | -52 | 22 | 18 |
| 30 Jun 19 | 3 | 31 | 24 | 19 |
| 31 Mar 19 | 5 | 57 | 24 | 20 |
| 31 Dec 18 | 5 | -46 | 25 | 21 |
| 30 Sep 18 | 5 | -73 | 23 | 22 |
| 30 Jun 18 | 6 | -125 | 22 | 24 |
| 31 Mar 18 | 4 | -133 | 21 | 23 |
| 31 Dec 17 | 3 | -20 | 20 | 24 |
| 30 Sep 17 | 4 | 47 | 19 | 26 |
| 30 Jun 17 | 3 | 64 | 19 | 26 |
| 31 Mar 17 | 4 | 100 | 22 | 29 |
| 31 Dec 16 | 6 | 34 | 28 | 36 |
| 30 Sep 16 | 6 | 25 | 33 | 42 |
| 30 Jun 16 | 7 | -20 | 36 | 47 |
| 31 Mar 16 | 8 | -54 | 36 | 47 |
| 31 Dec 15 | 7 | -47 | 29 | 43 |
| 30 Sep 15 | 7 | -45 | 24 | 41 |
| 30 Jun 15 | 6 | -39 | 20 | 38 |
| 31 Mar 15 | 5 | -39 | 19 | 38 |
| 31 Dec 14 | 5 | -36 | 18 | 38 |
| 30 Sep 14 | 5 | -45 | 17 | 35 |
| 30 Jun 14 | 5 | -46 | 17 | 33 |
| 31 Mar 14 | 5 | -44 | 16 | 30 |
| 31 Dec 13 | 4 | -44 | 16 | 27 |
| 30 Sep 13 | 4 | -30 | 15 | 22 |
Quality Earnings: LCTX is currently unprofitable.
Growing Profit Margin: LCTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LCTX is unprofitable, and losses have increased over the past 5 years at a rate of 4.5% per year.
Accelerating Growth: Unable to compare LCTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LCTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: LCTX has a negative Return on Equity (-36.19%), as it is currently unprofitable.